SLC6A3 and Parkinson disease: ,6 Biological and pathological markers for PD have shown promising performance in prodromal cohorts, with dopamine transporter (DaT) binding found to be reduced in ∼40% of patients with idiopathic RBD (iRBD)7,8 with 36.48% converting to PD within 4.7 years.9